Overcoming Unique Challenges in Evidence Development and Assessment for Access and Reimbursement/Coverage of Cell and Gene Therapies
An AMCP and Precision Value & Health Corporate Training Program
Brand and payer marketers, account executives, field and HQ-based HEOR leads, payer medical leads.
Over the last four –to five years, the market has seen the launch of numerous cell and gene therapies including Yescarta, Kymriah, Luxterna, and Zolgensma to name a few. The market for cell and gene therapy is poised to expand exponentially with over 1,100 cell and gene therapy companies who are actively conducting over 1,000 clinical trials.
Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies. These differences will impact how innovators develop evidence and manufacture and distribute products. Payers also need to adapt how they assess value, make coverage decisions and manage reimbursement.
Our half-day course will provide foundational information to equip the audience with how to best develop a compelling evidence package for cell and gene therapies, how payers will apply their assessment in decision-making, and how to best bridge the gap between these two. The program will be structured with a mixture of presentations and panel discussions.
At the completion of this program, participants should be able to:
- Understand the key components of the scientific underpinning of cell and gene therapy and future technologies.
- Understand nuances in develop value evidence for cell and gene therapies.
- Gain real customer insights. AMCP thought leaders and experts bring expertise into the evolving demands regarding payer evidence needs for cell and gene therapies.
Executive Vice President, Precision Value & Health
Ramesh Arjunji, PhD
Vice President, Value & Access, AvroBio
Rocio Manghani, MPH
Senior Vice President, Market Access, Gamida Cell
Philip Cyr, MPH
Senior Vice President, Precision Value & Health
Erin Lopato, PharmD, MPH
Senior Director, Precision Value & Health
About Precision Value & Health
Since 2013, Precision’s interdisciplinary teams have been advancing clinical, manufacturing and commercialization solutions to help innovators transform patient lives. We know that delivering a cell or gene therapy to market requires a nuanced, comprehensive and integrated approach, scientific and manufacturing expertise, and the right partner. That’s precisely why we’ve launched Precision ADVANCE, a collection of interconnected services and complementary teams uniquely focus on the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully bring cell or gene therapies to market. Learn more about how we accelerate clinical development with Precision for Medicine, optimize next-gen manufacturing with Project Farma and drive commercial success with Precision Value & Health.
About AMCP Corporate Training
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. Creating real-world, relevant training for life science companies — we build your health care business acumen so you can step out in confidence, equipped for customer engagements that drive positive patient outcomes. We’ve shaped our learning forums to connect you with thought leaders and experts. This, plus AMCP tools and resources, fast-tracks you to what’s relevant and keeps you informed about the newest insights. We’ll help you learn about the health care reforms that are most meaningful to you, your account teams and your clients — guiding you to customer-targeted solutions.
For questions about the corporate training program, please email firstname.lastname@example.org.